NasdaqGM:CSTLHealthcare
Castle Biosciences (CSTL) Q1 Loss Of US$14.5 Million Tests Profitability Narrative
Castle Biosciences (CSTL) opened Q1 2026 with revenue of US$83.7 million and a basic EPS loss of US$0.49, as net income excluding extra items came in at a loss of US$14.5 million. Over recent quarters, the company has seen revenue move between US$83.0 million and US$88.0 million while basic EPS has ranged from a loss of US$0.90 to a profit of US$0.16. This gives investors a clear view of how margins have been stretching and compressing as the business scales.
See our full analysis for Castle...